Petra Rueger

This inventor holds 25 USPTO granted patents and 9 published patent applications, plus 5 CIPO patents and 5 EPO patents, primarily in Biopharmaceutical Engineering. Top assignees: Hoffmann-La Roche Inc., Curis, Inc.. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Petra Rueger. Retrieved from https://idiyas.com/inventor/petra-rueger

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 25 (Patent Applications = 9)

% Patents Active = 64.0

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 10)

Average Co-Inventor Count = 5.9

ph-index = 6

Forward Citations = 112(Granted Patents)

Company Filing History:

20 out of 5,027

Hoffmann-La Roche Inc.

where one patent can have more than one assignee

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

Affinity Chromatography

Complement Factor

Transferrin Receptor

Blood Brain Barrier

Pharmaceutical Agents

Protein Kinases

Hedgehog Protein

Amino Derivatives

Antibody Engineering

Hydrophobic Interaction

Monovalent Modules

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735497 - BISPECIFIC ANTI-HUMAN A-BETA/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE (2026-09-15),

2. 12735485 - BISPECIFIC ANTIGEN BINDING MOLECULES TARGETING OX40 AND FAP (2026-09-15),

3. 12522637 - COMPLEMENT FACTOR BASED AFFINITY CHROMATOGRAPHY (2026-01-13),

4. 12358997 - Bispecific anti-human A-beta/anti-human transferrin receptor antibodies (2025-07-15),

5. 12030952 - Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use (2024-07-09),

6. 11945839 - Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography (2024-04-02),

7. 11814409 - Fc-receptor based affinity chromatography (2023-11-14),

8. 11787868 - Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use (2023-10-17),

9. 11780919 - Bispecific antigen binding molecules targeting OX40 and FAP (2023-10-10),

10. 11603411 - Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use (2023-03-14),

11. 11440942 - Complement factor based affinity chromatography (2022-09-13),

12. 10941205 - Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use (2021-03-09),

13. 10364292 - Monovalent blood brain barrier shuttle modules (2019-07-30),

14. 10093714 - Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereof (2018-10-09),

15. 10011644 - Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereof (2018-07-03),

Title: Petra Rueger: Innovating in Bispecific Antibody Development

Introduction: Petra Rueger, based in Penzberg, Germany, is an accomplished inventor with an impressive portfolio of 21 patents. His work primarily focuses on the innovative field of bispecific antibodies, contributing significantly to therapeutic advancements in medicine.

Latest Patents: Among his latest inventions are the "Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use," where he provides solutions for the effective use of bispecific antibodies in medical applications. Another significant patent is "Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography," which outlines methods to separate multispecific CrossMab antibodies from light chain mispaired variants. This innovative approach enhances the purification process in the development of therapeutic antibodies.

Career Highlights: Petra has made substantial advancements in the biopharmaceutical industry through his roles at reputable companies such as Hoffmann-La Roche Inc. and Curis, Inc. His contributions have aided in developing targeted therapies that address critical medical needs.

Collaborations: Throughout his career, Petra has collaborated with esteemed professionals, including Wolfgang Schaefer and Christian Klein. These partnerships have fostered a creative environment for innovation, leading to groundbreaking research and patent development.

Conclusion: Petra Rueger's work exemplifies the importance of innovation in the fields of biotechnology and pharmaceuticals. His numerous patents, coupled with a robust career and collaborations, underscore his vital role in advancing medical technology through bispecific antibody development.

Profile summary based on public USPTO records.